Steve Pagliuca confirms interest in purchasing Connecticut Sun, but says no deal in place
Pagliuca said that their offer is subject to obtaining the required league approvals.
Advertisement
While that is the case with all league transactions, it could be especially important in this case, as Pagliuca's group is reportedly intending to relocate the franchise out of Uncasville, Conn., the current home of the Sun, and to Boston. In his statement, Pagliuca did not confirm that Boston would be the future site of the franchise, but he did say that their offer would 'keep New England's WNBA team in New England.' He also said PagsGroups' bid has support from both Massachusetts governor Maura Healy and Rhode Island governor Daniel McKee.
'Central to our proposal is enabling the Sun to play in larger capacity arenas in New England,' Pagliuca said in a statement. 'We believe our record-setting offer and deep commitment to growing the WNBA in the region that is home to the most passionate basketball fans in the nation will significantly benefit the league, the team, and all its fans.'
The Sun played in Boston's TD Garden, which has a capacity of 19,156, in each of the past two seasons, with both regular-season games being sellouts.
Earlier Sunday, Connecticut Sun president Jennifer Rizzotti said that a sale by the Mohegan Tribe is 'not quite at the finish line yet,' but that the Tribe had explored different investment options this summer.
'If Boston was an option, it's hard to argue that they're not a city that's viable for a WNBA franchise,' said Rizzotti, who confirmed that the Sun will play in Connecticut for the 2026 season.
Pagliuca, a minority owner of the NBA's Boston Celtics, is reportedly trying to buy the Sun for $325 million — a would-be record sale for a professional women's sports franchise — and plans to contribute $100 million for a practice facility.
Here's an important update on our possible acquisition of the Connecticut Sun. pic.twitter.com/GA1Q2tqwNP
— Steve Pagliuca (@pagsceltics) August 3, 2025
The WNBA said in a statement on Saturday that relocation decisions are 'made by the WNBA Board of Governors and not by individual teams.' They added that while no groups from Boston bid for a franchise ahead of the league's Jan. 31 deadline, that the Celtics' incoming prospective ownership group — which does not include Pagliuca — has also reached out to the WNBA.
Advertisement
'(They) asked that Boston receive strong consideration for a WNBA franchise at the appropriate time,' the statement read.
Pagliuca, 70, is a longtime minority owner of the Celtics, having partnered with owner Wyc Grousbeck's family in 2002. He was one of the finalists for the team's majority sale, but in March, the Celtics were sold to Bill Chisholm, the managing partner of Symphony Technology Group, for what, at the time, was an NBA-record $6.1 billion.
When news was made public that Pagliuca did not have the winning Celtics bid, he said in a lengthy statement that he was 'saddened' to find out that he was not selected to steward the NBA franchise in the future.
Now, it appears his focus is on the WNBA.
'This approval has not been obtained thus far, and we cannot proceed without it. We will respect, cooperate with, and abide by all league rules and decisions on these matters,' Pagliuca said. 'As passionate basketball fans and strong believers in women's professional sports, we remain excited by this opportunity and would be honored to serve as the next stewards of this franchise, if the transaction can be approved.'
The potential $325 million price tag would be significant for the Mohegan Tribe. Expansion groups in Cleveland, Detroit and Philadelphia all paid a reported $250 million in expansion fees to join the league in 2028, 2029, and 2030. The Sun moved to Connecticut from Orlando ahead of the 2003 season after the Tribe purchased the team for $10 million.
They were the WNBA's first independently-owned franchise as well as the first Native American Tribe to own a professional American sports team.
Connecticut has made the playoffs in eight straight seasons and at least the semifinals in the last six years, though both streaks appear to be in serious jeopardy considering the Sun currently have the league's worst record.
Advertisement
'I know there's still uncertainty about the future,' Rizzotti said, 'but our loyal fans, they're excited to be able to watch this team grow and get into Year Two of this retooling of the roster and see where we can go. And if it ends up being our last year here, we're going to make sure we blow it out.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Lucid Diagnostics to Participate in Upcoming Investor Conferences
NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences: 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference 1x1 Meetings: August 11-12, 2025 Location: Virtual Canaccord Genuity 45th Annual Growth Conference Fireside Chat: August 13, 2025, at 2:30 PM ET Location: Boston, MA The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website. A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast. About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit and for more information about its parent company PAVmed, please visit View original content to download multimedia: SOURCE Lucid Diagnostics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
2025 WNBA trade deadline candidates include Marina Mabrey, Aaliyah Edwards
The 2025 WNBA trade deadline is quickly approaching, and there are several players to monitor as movement heats up. For the last several weeks, things have been fairly quiet on the trade front. In June, the Seattle Storm traded center Li Yueru to the Wings, and the Las Vegas Aces picked up Wings forward Nalyssa Smith in exchange for the team's 2027 first-round draft pick. However, on Sunday, the action picked up again. The Minnesota Lynx acquired Wings guard DiJonai Carrington in a three-player trade that also included Minnesota's 2027 second-round pick. Carrington's could signal another wave of moves. As the August 7 deadline approaches, here are some names to monitor: Marina Mabrey, guard, Connecticut Sun Mabrey made headlines over the offseason with a trade request. Connecticut brought Mabrey to the team during the 2024 season with the hopes of adding her to its quest for a championship. The title didn't happev and, in the offseason, the Sun parted ways with every starter and their head coach. Predictably, she asked for a trade, but Connecticut denied her request. That led to her agent ripping the franchise publicly, insinuating the team was forcing her to play when she didn't want to be there. Things have calmed down since then, and now a trade doesn't feel likely to happen. Still, it wouldn't be surprising if Mabrey brings the request back to the table. Aaliyah Edwards, forward, Washington Mystics Edwards was drafted by the Mystics with the sixth overall pick in the 2024 WNBA draft. However, after starting 15-plus games last season, her minutes have diminished and so has her production. The former UConn Huskies forward is averaging career lows in nearly every major category, including minutes (13) and points (six). Edwards began the season with an injury, which forced the Mystics to turn to rookie Kiki Iriafen a lot sooner. Iriafen took advantage and carved out a lane in Washington's starting lineup. Edwards was left on the outside looking in as Washington turned to Iriafen and veterans Shakira Austin and Stefanie Dolson. In July, ESPN reported Washington had begun accepting offers for the second-year forward. If she is moved, the Valkyries or Chicago Sky, who could use productive depth, make sense. Other WNBA trade candidates Alysha Clark, guard, Seattle Storm: Clark has struggled since re-joining the Storm earlier this year, following three seasons between the Mystics and the Las Vegas Aces. She was pulled from the starting lineup after seven games and is averaging three points per game, production that hasn't been seen since her rookie season. Damiris Dantas, forward, Indiana Fever: It's hard to gauge what the Fever's plan is for Dantas. Her minutes have been all over the place and so has her production. That said, the Fever seem to have patience. A move probably isn't likely, but for a team wanting to continually stay in the contender conversations, reorganizing the bottom of the roster isn't out of reach. Kalani Brown, center, Phoenix Mercury: The Phoenix Mercury traded for Brown when they brought over Satou Sabally in a blockbuster trade in February. It was widely assumed the former Wings center would take over playing the five spot with franchise player Brittney Griner off to Atlanta, but that hasn't been the case. Brown has started one game in 2025, and her minutes have been inconsistent since early June. This article originally appeared on USA TODAY: 2025 WNBA trade deadline candidates include Mabrey, Edwards
Yahoo
15 minutes ago
- Yahoo
Broken String Biosciences Renews Commitment to NIST Genome Editing Consortium, Bolstering Efforts to Standardize Gene Editing Safety
BOSTON & CAMBRIDGE, England, August 05, 2025--(BUSINESS WIRE)--Broken String Biosciences ("Broken String"), a leader in advancing gene editing safety, today announced its formal re-engagement as a member of the National Institute of Standards and Technology (NIST) Genome Editing Consortium. Broken String plays a key role in developing the gold-standard of safety testing for gene-editing therapies, based on its INDUCE-seq® platform. INDUCE-seq is commercially deployed today to address a critical challenge in the safe development of gene therapies: identifying unintended edits that may activate oncogenes or disable tumor suppressors. Broken String's participation in the NIST Genome Editing Consortium is part of the company's efforts to shape industry-wide safety standards for emerging genome editing technologies, including CRISPR, base editing, and prime editing. The company continues to partner with the consortia and other leaders in the field to publish findings and engage with regulators to promote greater understanding and adoption of its breakthrough technology. One such effort is the cross-sector Health and Environmental Sciences Institute Cell and Gene Therapy – Tracking, Circulation, & Safety (HESI CT-TRACS) Committee, where 30 like-minded partner companies – including major biopharma partners – are helping advance breakthrough technologies that improve human health. "Gene editing holds enormous promise, but without standardized tools to assess both on- and off-target edits, developers will continue to face challenges in demonstrating safety to regulators and the public," said Felix Dobbs, CEO and co-founder of Broken String. "Our ongoing collaboration with NIST and leading industry partners such as AstraZeneca and Novartis underscores the urgency of our work. We believe that implementing INDUCE-seq early in the development process can significantly reduce the risk of costly regulatory holds and adverse effects, protecting both patient safety and business investment. This is how we help realize the full potential of life-changing gene therapies." This renewed collaboration underscores Broken String's commitment to advancing the safety and standardization of gene-editing therapies through its innovative INDUCE-seq platform. INDUCE-seq is a technology intended to help standardize the gene therapy industry. The NIST Genome Editing Consortium is dedicated to generating crucial data that Broken String believes will highlight the superior features of INDUCE-seq, a PCR-free platform that enables unbiased, high-resolution detection of double-strand DNA breaks (DSBs). This includes its reproducibility, robustness, and sensitivity, surpassing existing approaches in off-target detection. For more information on the NIST Genome Editing Consortium, visit About Broken String Biosciences Broken String Biosciences is advancing more precise, safe, and effective cell and gene therapies through its cutting-edge technology platforms. The company's core platform, INDUCE-seq®, was developed as the new gold standard for precise mapping of DNA breaks to measure and quantify on- and off-target genetic edits, crucial for ensuring the efficacy and safety of advanced therapies from discovery through commercialization. Broken String Biosciences was spun out of Cardiff University by genomics experts. The company is venture-funded and has raised $20 million to date. To learn more about the company, visit About INDUCE-seq® Broken String Bioscience's INDUCE-seq® enables direct, cell-based measurements of on-target and off-target edits directly from a clinically relevant biological system. This ensures therapy developers can characterize safety and efficacy as early as discovery, before committing substantial budgets and time to preclinical or clinical trials. The technology also allows for off-target assessments tailored to a patient's specific genotype, enabling developers to bring safety evaluations closer to the patient. This capability supports faster, more targeted treatments, helping to accelerate progress in life-saving therapies. Through Broken String's Early Access Program, select partners with gene editing therapies in development can experience many of INDUCE-seq®'s advantages over existing approaches. For more information, visit View source version on Contacts Media Contact brokenstringbio@ Sign in to access your portfolio
